Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinoma

8 Jul 2022

Abstract excerpt

BACKGROUND: We aimed to identify the relationship between thyroid transcription factor-1 (TTF-1) expression of lung adenocarcinoma and the efficacy of immune-checkpoint inhibitor (ICI) therapy. METHODS: This retrospective multicenter study comprised patients with advanced lung adenocarcinoma treated with ICI monotherapy. We collected clinical medical records including data on TTF-1 expression and analyzed the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35808895
DOI: 10.1111/1759-7714.14560

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinomaPMID 35808895Read ↗

The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinomaSemantic proximity Read ↗

Thyroid transcription factor 1 (TTF-1) negativity as a predictor of unfavorable response to EGFR-TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations.Semantic proximity Read ↗

The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.Semantic proximity Read ↗

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.Semantic proximity Read ↗

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.Semantic proximity Read ↗

Prognostic and predictive value ofTTF-1 expression in patients with recurrent or advanced lung adenocarcinoma without sensitizing EGFR mutations or ALK translocation treated with platinum-based chemotherapySemantic proximity Read ↗

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung AdenocarcinomasSemantic proximity Read ↗

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.Semantic proximity Read ↗

Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.Semantic proximity Read ↗

Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung AdenocarcinomaSemantic proximity Read ↗

Relationship of tumor PD-L1 expression with<i>EGFR</i>wild-type status and poor prognosis in lung adenocarcinomaSemantic proximity Read ↗

TCF-1+ PD-1+ CD8+T Cells Are Associated With The Response To PD-1 Blockade In Non-Small Cell Lung Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.